<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p199" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_199{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_199{left:306px;bottom:30px;}
#t3_199{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_199{left:346px;bottom:30px;}
#t5_199{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_199{left:517px;bottom:30px;}
#t7_199{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_199{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_199{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_199{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_199{left:35px;bottom:777px;letter-spacing:-0.01px;word-spacing:-0.57px;}
#tc_199{left:35px;bottom:754px;letter-spacing:0.1px;word-spacing:-0.33px;}
#td_199{left:35px;bottom:731px;letter-spacing:-0.02px;word-spacing:0.21px;}
#te_199{left:328px;bottom:738px;letter-spacing:-0.01px;}
#tf_199{left:35px;bottom:690px;letter-spacing:0.11px;word-spacing:-0.41px;}
#tg_199{left:35px;bottom:667px;word-spacing:-0.52px;}
#th_199{left:35px;bottom:645px;letter-spacing:0.12px;word-spacing:0.07px;}
#ti_199{left:35px;bottom:622px;letter-spacing:0.04px;word-spacing:0.15px;}
#tj_199{left:444px;bottom:622px;}
#tk_199{left:453px;bottom:622px;letter-spacing:0.16px;word-spacing:0.03px;}
#tl_199{left:35px;bottom:599px;letter-spacing:-0.04px;}
#tm_199{left:94px;bottom:606px;letter-spacing:-0.01px;}
#tn_199{left:117px;bottom:599px;letter-spacing:0.01px;word-spacing:0.17px;}
#to_199{left:35px;bottom:575px;letter-spacing:0.05px;}
#tp_199{left:92px;bottom:583px;letter-spacing:-0.01px;}
#tq_199{left:115px;bottom:575px;letter-spacing:0.09px;word-spacing:0.1px;}
#tr_199{left:35px;bottom:552px;letter-spacing:-0.11px;}
#ts_199{left:114px;bottom:552px;letter-spacing:-0.25px;}
#tt_199{left:164px;bottom:552px;letter-spacing:0.08px;word-spacing:0.11px;}
#tu_199{left:35px;bottom:529px;letter-spacing:-0.02px;word-spacing:0.2px;}
#tv_199{left:460px;bottom:529px;letter-spacing:-0.25px;}
#tw_199{left:510px;bottom:529px;letter-spacing:0.05px;}
#tx_199{left:35px;bottom:506px;letter-spacing:-0.05px;}
#ty_199{left:101px;bottom:513px;letter-spacing:-0.01px;}
#tz_199{left:125px;bottom:506px;letter-spacing:0.03px;word-spacing:0.16px;}
#t10_199{left:35px;bottom:482px;letter-spacing:-0.08px;word-spacing:-0.97px;}
#t11_199{left:214px;bottom:482px;letter-spacing:-0.2px;}
#t12_199{left:252px;bottom:482px;letter-spacing:0.1px;word-spacing:-0.95px;}
#t13_199{left:35px;bottom:459px;letter-spacing:0.08px;word-spacing:0.11px;}
#t14_199{left:35px;bottom:436px;letter-spacing:0.13px;word-spacing:-0.56px;}
#t15_199{left:35px;bottom:413px;letter-spacing:0.03px;word-spacing:0.15px;}
#t16_199{left:35px;bottom:390px;letter-spacing:0.17px;word-spacing:0.02px;}
#t17_199{left:35px;bottom:366px;word-spacing:0.2px;}
#t18_199{left:220px;bottom:374px;letter-spacing:-0.01px;}
#t19_199{left:35px;bottom:326px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1a_199{left:35px;bottom:303px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1b_199{left:35px;bottom:280px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1c_199{left:35px;bottom:256px;word-spacing:0.19px;}
#t1d_199{left:35px;bottom:233px;letter-spacing:0.04px;word-spacing:0.14px;}
#t1e_199{left:35px;bottom:210px;letter-spacing:0.13px;word-spacing:-0.18px;}
#t1f_199{left:286px;bottom:217px;}
#t1g_199{left:331px;bottom:210px;letter-spacing:-0.03px;word-spacing:0.22px;}
#t1h_199{left:35px;bottom:187px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1i_199{left:35px;bottom:163px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1j_199{left:35px;bottom:140px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1k_199{left:335px;bottom:148px;letter-spacing:-0.01px;}
#t1l_199{left:358px;bottom:140px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1m_199{left:35px;bottom:117px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1n_199{left:35px;bottom:94px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1o_199{left:401px;bottom:101px;}
#t1p_199{left:446px;bottom:94px;letter-spacing:-0.15px;word-spacing:0.34px;}
#t1q_199{left:35px;bottom:71px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1r_199{left:618px;bottom:777px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1s_199{left:618px;bottom:754px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1t_199{left:865px;bottom:761px;letter-spacing:-0.01px;}
#t1u_199{left:889px;bottom:754px;letter-spacing:0.05px;word-spacing:0.13px;}
#t1v_199{left:985px;bottom:761px;letter-spacing:-0.01px;}
#t1w_199{left:1008px;bottom:754px;word-spacing:0.19px;}
#t1x_199{left:618px;bottom:731px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1y_199{left:618px;bottom:707px;letter-spacing:0.16px;word-spacing:-0.75px;}
#t1z_199{left:618px;bottom:684px;letter-spacing:-0.02px;word-spacing:0.22px;}
#t20_199{left:618px;bottom:661px;letter-spacing:0.11px;word-spacing:0.08px;}
#t21_199{left:618px;bottom:638px;letter-spacing:0.1px;word-spacing:0.09px;}
#t22_199{left:972px;bottom:645px;letter-spacing:0.1px;}
#t23_199{left:1017px;bottom:638px;letter-spacing:0.08px;word-spacing:0.11px;}
#t24_199{left:618px;bottom:614px;letter-spacing:0.22px;word-spacing:-0.04px;}
#t25_199{left:618px;bottom:591px;letter-spacing:-0.01px;word-spacing:0.2px;}
#t26_199{left:618px;bottom:550px;letter-spacing:-0.17px;word-spacing:1.43px;}
#t27_199{left:618px;bottom:522px;letter-spacing:0.09px;word-spacing:-0.81px;}
#t28_199{left:1124px;bottom:529px;letter-spacing:-0.51px;}
#t29_199{left:1165px;bottom:522px;letter-spacing:-1.08px;}
#t2a_199{left:618px;bottom:498px;letter-spacing:0.14px;word-spacing:-0.69px;}
#t2b_199{left:983px;bottom:506px;letter-spacing:-0.01px;}
#t2c_199{left:1006px;bottom:498px;letter-spacing:0.22px;word-spacing:-0.02px;}
#t2d_199{left:618px;bottom:475px;letter-spacing:0.03px;word-spacing:0.05px;}
#t2e_199{left:618px;bottom:452px;letter-spacing:0.02px;word-spacing:0.17px;}
#t2f_199{left:772px;bottom:459px;letter-spacing:-0.01px;}
#t2g_199{left:796px;bottom:452px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2h_199{left:618px;bottom:429px;letter-spacing:0.07px;}
#t2i_199{left:702px;bottom:436px;letter-spacing:-0.01px;}
#t2j_199{left:725px;bottom:429px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2k_199{left:618px;bottom:405px;letter-spacing:0.14px;}
#t2l_199{left:719px;bottom:413px;letter-spacing:-0.01px;}
#t2m_199{left:742px;bottom:405px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2n_199{left:618px;bottom:382px;letter-spacing:-0.02px;word-spacing:0.21px;}
#t2o_199{left:869px;bottom:390px;letter-spacing:-0.01px;}
#t2p_199{left:892px;bottom:382px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2q_199{left:618px;bottom:359px;}
#t2r_199{left:618px;bottom:319px;letter-spacing:0.32px;word-spacing:-0.14px;}
#t2s_199{left:618px;bottom:289px;letter-spacing:0.02px;word-spacing:0.18px;}
#t2t_199{left:901px;bottom:297px;letter-spacing:0.61px;}
#t2u_199{left:915px;bottom:289px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2v_199{left:618px;bottom:266px;letter-spacing:0.33px;word-spacing:-0.13px;}
#t2w_199{left:787px;bottom:274px;letter-spacing:-0.01px;}
#t2x_199{left:810px;bottom:266px;letter-spacing:0.15px;word-spacing:0.05px;}
#t2y_199{left:618px;bottom:243px;letter-spacing:0.17px;word-spacing:-0.78px;}
#t2z_199{left:618px;bottom:220px;letter-spacing:0.08px;word-spacing:0.11px;}
#t30_199{left:618px;bottom:196px;letter-spacing:0.09px;word-spacing:-0.94px;}
#t31_199{left:618px;bottom:173px;letter-spacing:0.15px;word-spacing:-0.67px;}
#t32_199{left:618px;bottom:150px;letter-spacing:0.01px;word-spacing:-0.55px;}
#t33_199{left:618px;bottom:128px;letter-spacing:0.07px;word-spacing:-1px;}
#t34_199{left:618px;bottom:105px;letter-spacing:0.05px;word-spacing:0.13px;}
#t35_199{left:618px;bottom:82px;letter-spacing:0.1px;word-spacing:-0.87px;}
#t36_199{left:618px;bottom:58px;letter-spacing:0.13px;word-spacing:0.05px;}
#t37_199{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_199{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_199{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_199{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_199{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_199{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_199{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_199{font-size:17px;font-family:ArialMT_k0;color:#000;}
.s7_199{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s8_199{font-size:20px;font-family:Arial-BoldMT_5te;color:#000;}
.s9_199{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts199" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg199Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg199" style="-webkit-user-select: none;"><object width="1210" height="935" data="199/199.svg" type="image/svg+xml" id="pdf199" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_199" class="t s0_199">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_199" class="t s1_199">© </span>
<span id="t3_199" class="t s0_199">(NCCN </span>
<span id="t4_199" class="t s1_199">© </span>
<span id="t5_199" class="t s0_199">), All rights reserved. NCCN Guidelines </span>
<span id="t6_199" class="t s1_199">® </span>
<span id="t7_199" class="t s0_199">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_199" class="t s2_199">NCCN Guidelines Version 4.2024 </span>
<span id="t9_199" class="t s2_199">Head and Neck Cancers </span>
<span id="ta_199" class="t s3_199">MS-58 </span>
<span id="tb_199" class="t s4_199">are currently only available in abstract form. Fam-trastuzumab deruxtecan- </span>
<span id="tc_199" class="t s4_199">nxki is also supported by a dose-expansion, phase I study that included 8 </span>
<span id="td_199" class="t s4_199">participants with salivary gland tumors. </span>
<span id="te_199" class="t s5_199">724 </span>
<span id="tf_199" class="t s4_199">Pembrolizumab is an option for patients with previously treated TMB-H or </span>
<span id="tg_199" class="t s4_199">MSI-H/dMMR recurrent, unresectable, or metastatic salivary gland cancer, </span>
<span id="th_199" class="t s4_199">based on results from the phase II KEYNOTE-158 trial, which included </span>
<span id="ti_199" class="t s4_199">three patients with salivary gland cancer and TMB-H (</span><span id="tj_199" class="t s6_199">≥</span><span id="tk_199" class="t s4_199">10 mut/Mb) </span>
<span id="tl_199" class="t s4_199">disease </span>
<span id="tm_199" class="t s5_199">558 </span>
<span id="tn_199" class="t s4_199">and two patients with MSI-H/dMMR advanced salivary gland </span>
<span id="to_199" class="t s4_199">cancer. </span>
<span id="tp_199" class="t s5_199">673 </span>
<span id="tq_199" class="t s4_199">Combination dabrafenib/trametinib is FDA-approved for all </span>
<span id="tr_199" class="t s4_199">advanced </span><span id="ts_199" class="t s7_199">BRAF </span><span id="tt_199" class="t s4_199">V600E-mutated tumors, and a case report supports its </span>
<span id="tu_199" class="t s4_199">use for widely metastatic salivary duct carcinoma that is </span><span id="tv_199" class="t s7_199">BRAF </span><span id="tw_199" class="t s4_199">V600E- </span>
<span id="tx_199" class="t s4_199">mutated. </span>
<span id="ty_199" class="t s5_199">725 </span>
<span id="tz_199" class="t s4_199">Similarly, selpercatinib is FDA-approved for all locally </span>
<span id="t10_199" class="t s4_199">advanced or metastatic </span><span id="t11_199" class="t s7_199">RET </span><span id="t12_199" class="t s4_199">gene fusion-positive solid tumors, and its use </span>
<span id="t13_199" class="t s4_199">for patients with recurrent, unresectable, or metastatic salivary gland </span>
<span id="t14_199" class="t s4_199">cancer is supported by the ongoing phase I/II LIBRETTO-001 trial, which, </span>
<span id="t15_199" class="t s4_199">at the time of the most recent analysis, included 4 patients with a salivary </span>
<span id="t16_199" class="t s4_199">gland tumor and an ORR of 50% for these patients (independent review </span>
<span id="t17_199" class="t s4_199">committee assessment). </span>
<span id="t18_199" class="t s5_199">726 </span>
<span id="t19_199" class="t s4_199">Other systemic therapy options may be used for palliation in advanced </span>
<span id="t1a_199" class="t s4_199">disease. Various combinations of chemotherapy agents (ie, </span>
<span id="t1b_199" class="t s4_199">cisplatin/cyclophosphamide/doxorubicin, cisplatin/vinorelbine, </span>
<span id="t1c_199" class="t s4_199">carboplatin/paclitaxel, carboplatin/gemcitabine) have been shown in small </span>
<span id="t1d_199" class="t s4_199">series to be active for some salivary gland malignant histologies, with </span>
<span id="t1e_199" class="t s4_199">ORRs ranging from 24% to 60%. </span>
<span id="t1f_199" class="t s5_199">727-731 </span>
<span id="t1g_199" class="t s4_199">A small phase II trial also supports </span>
<span id="t1h_199" class="t s4_199">use of paclitaxel monotherapy based on an RR of 26% for patients with </span>
<span id="t1i_199" class="t s4_199">mucoepidermoid or adenocarcinoma histology; no responses were </span>
<span id="t1j_199" class="t s4_199">observed for adenoid cystic carcinoma. </span>
<span id="t1k_199" class="t s5_199">732 </span>
<span id="t1l_199" class="t s4_199">Use of certain tyrosine kinase </span>
<span id="t1m_199" class="t s4_199">inhibitors such as axitinib (with or without avelumab) and sorafenib have </span>
<span id="t1n_199" class="t s4_199">been evaluated in nonrandomized phase II trials </span>
<span id="t1o_199" class="t s5_199">733-735 </span>
<span id="t1p_199" class="t s4_199">and are </span>
<span id="t1q_199" class="t s4_199">recommended by the panel as category 2B options for patients with </span>
<span id="t1r_199" class="t s4_199">unresectable, metastatic, or recurrent salivary gland tumors (useful in </span>
<span id="t1s_199" class="t s4_199">certain circumstances). Sunitinib </span>
<span id="t1t_199" class="t s5_199">736 </span>
<span id="t1u_199" class="t s4_199">and dovitinib </span>
<span id="t1v_199" class="t s5_199">737 </span>
<span id="t1w_199" class="t s4_199">have also been </span>
<span id="t1x_199" class="t s4_199">evaluated in phase II trials, but larger trials are needed to determine the </span>
<span id="t1y_199" class="t s4_199">efficacy of these options. Lenvatinib as a treatment option for recurrent or </span>
<span id="t1z_199" class="t s4_199">metastatic adenoid cystic carcinoma has been evaluated in two phase II </span>
<span id="t20_199" class="t s4_199">trials, which showed disease control rates of 88% (partial response of </span>
<span id="t21_199" class="t s4_199">11.5%–15.6%, stable disease in 75%–76.9%). </span>
<span id="t22_199" class="t s5_199">738,739 </span>
<span id="t23_199" class="t s4_199">Based on these </span>
<span id="t24_199" class="t s4_199">results and lack of other evidence-based options for recurrent or </span>
<span id="t25_199" class="t s4_199">metastatic adenoid cystic carcinoma, lenvatinib is a category 2B option. </span>
<span id="t26_199" class="t s8_199">Mucosal Melanoma of the Head and Neck </span>
<span id="t27_199" class="t s4_199">MM is a rare but highly aggressive neoplasm with a poor prognosis. </span>
<span id="t28_199" class="t s5_199">740,741 </span>
<span id="t29_199" class="t s4_199">It </span>
<span id="t2a_199" class="t s4_199">occurs throughout the upper aerodigestive tract. </span>
<span id="t2b_199" class="t s5_199">742 </span>
<span id="t2c_199" class="t s4_199">Most MM (70%–80%) </span>
<span id="t2d_199" class="t s4_199">occur in the nasal cavity or paranasal sinuses, followed by the oral cavity, </span>
<span id="t2e_199" class="t s4_199">pharynx, and larynx. </span>
<span id="t2f_199" class="t s5_199">743 </span>
<span id="t2g_199" class="t s4_199">The incidence of nasal cavity MM appears to be </span>
<span id="t2h_199" class="t s4_199">increasing. </span>
<span id="t2i_199" class="t s5_199">740 </span>
<span id="t2j_199" class="t s4_199">Sinonasal MM is typically confined to the primary site at </span>
<span id="t2k_199" class="t s4_199">presentation. </span>
<span id="t2l_199" class="t s5_199">744 </span>
<span id="t2m_199" class="t s4_199">Oral cavity MM more frequently presents with clinically </span>
<span id="t2n_199" class="t s4_199">apparent lymph node metastasis. </span>
<span id="t2o_199" class="t s5_199">745 </span>
<span id="t2p_199" class="t s4_199">No etiologic risk factors are yet </span>
<span id="t2q_199" class="t s4_199">apparent. </span>
<span id="t2r_199" class="t s3_199">Workup and Staging </span>
<span id="t2s_199" class="t s4_199">The AJCC Cancer Staging Manual (8 </span>
<span id="t2t_199" class="t s5_199">th </span>
<span id="t2u_199" class="t s4_199">edition) includes a staging system </span>
<span id="t2v_199" class="t s4_199">for MM (see Table 9). </span>
<span id="t2w_199" class="t s5_199">391 </span>
<span id="t2x_199" class="t s4_199">The AJCC staging recognizes two key factors </span>
<span id="t2y_199" class="t s4_199">specific to MM: 1) the poor prognosis of MM even with a limited burden of </span>
<span id="t2z_199" class="t s4_199">disease from the primary tumor; and 2) there is still some gradation of </span>
<span id="t30_199" class="t s4_199">survival based on the burden of disease as reflected in local, regional, and </span>
<span id="t31_199" class="t s4_199">distant extent. Thus, the AJCC staging system for MM begins with T3, N0 </span>
<span id="t32_199" class="t s4_199">disease as the most limited form of disease (T staging similar to anaplastic </span>
<span id="t33_199" class="t s4_199">thyroid carcinoma), and the staging reflects the local burden of disease, as </span>
<span id="t34_199" class="t s4_199">well as regional and distant extent. In addition, the AJCC staging system </span>
<span id="t35_199" class="t s4_199">reflects the fact that MM occurs at all mucosal sites in the H&amp;N. Therefore, </span>
<span id="t36_199" class="t s4_199">rules for classifying, staging, and surgical principles should be based on </span>
<span id="t37_199" class="t s9_199">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
